Cheyenne Journal

Inflammatory Bowel Disease Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Eli Lilly and Company, Gilead, Galapagos, Applied Inc.

 Breaking News
  • No posts were found

Inflammatory Bowel Disease Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Eli Lilly and Company, Gilead, Galapagos, Applied Inc.

May 25
19:28 2023
Inflammatory Bowel Disease Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Eli Lilly and Company, Gilead, Galapagos, Applied Inc.
DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Bowel Disease.

DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Bowel Disease Market Forecast

 

Some of the key facts of the Inflammatory Bowel Disease Market Report: 

  • The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • During the year 2021, there were 3,835,000 prevalent cases of IBD in the 7MM. In all of the regions, this count is predicted to rise during the projection period
  • There were 634,000 and 1,021,000 prevalent cases of CD and UC, respectively, in the EU-5 region in 2021
  • It was discovered that the overall diagnosed prevalence of IBD in the 7MM increased steadily during the course of the study. In the 7MM, 2,743,000 cases of IBD were identified in 2021. In 2021, there were the most diagnosed cases of IBD in the United States. In the US, there were over 1,323,000 diagnosed cases of IBD in 2021
  • The introduction of numerous important medications during the past ten years has changed how inflammatory bowel disease is managed. Adalimumab, infliximab, and vedolizumab medications like HUMIRA (adalimumab, AbbVie), REMICADE (Janssen), and ENTYVIO (Takeda) have all assisted patients in achieving significant endpoints including clinical remission and mucosal healing.
  • Key Inflammatory Bowel Disease Companies: Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
  • Key Inflammatory Bowel Disease Therapies: Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others
  • The Inflammatory Bowel Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

 

Inflammatory Bowel Disease Overview

Chronic and complicated, inflammatory bowel disease (IBD) is brought on by immune system dysregulation brought on by genetic, epigenetic, microbial, and environmental variables.

 

Get a Free sample for the Inflammatory Bowel Disease Market Report 

https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market

 

Inflammatory Bowel Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Inflammatory Bowel Disease
  • Prevalent Cases of Inflammatory Bowel Disease by severity
  • Gender-specific Prevalence of Inflammatory Bowel Disease
  • Diagnosed Cases of Episodic and Chronic Inflammatory Bowel Disease

 

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Epidemiology Forecast

 

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Inflammatory Bowel Disease Therapies and Key Companies

  • Mirikizumab: Eli Lilly and Company
  • Filgotinib: Gilead/ Galapagos
  • AMT-101: Applied Molecular Transport
  • PN-943: Protagonist Therapeutics
  • Tremfya: Janssen
  • Brazikumab: AstraZeneca

 

Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ Inflammatory Bowel Disease Treatment Market

 

Scope of the Inflammatory Bowel Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Inflammatory Bowel Disease Companies: Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
  • Key Inflammatory Bowel Disease Therapies: Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others
  • Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies
  • Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement 

 

To know more about Inflammatory Bowel Disease companies working in the treatment market, visit @ Inflammatory Bowel Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Inflammatory Bowel Disease Market Report Introduction

2. Executive Summary for Inflammatory Bowel Disease

3. SWOT analysis of Inflammatory Bowel Disease

4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance

5. Inflammatory Bowel Disease Market Overview at a Glance

6. Inflammatory Bowel Disease Disease Background and Overview

7. Inflammatory Bowel Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Bowel Disease 

9. Inflammatory Bowel Disease Current Treatment and Medical Practices

10. Inflammatory Bowel Disease Unmet Needs

11. Inflammatory Bowel Disease Emerging Therapies

12. Inflammatory Bowel Disease Market Outlook

13. Country-Wise Inflammatory Bowel Disease Market Analysis (2019–2032)

14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies

15. Inflammatory Bowel Disease Market Drivers

16. Inflammatory Bowel Disease Market Barriers

17.  Inflammatory Bowel Disease Appendix

18. Inflammatory Bowel Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories